|Articles|November 15, 2016
SCRS Welcomes GlaxoSmithKline as a Global Impact Partner
The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP).
Advertisement
The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
2
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
3
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
4
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
5